Travere Therapeutics, the IgA Nephropathy Foundation, and NephCure Kidney International Partner to Launch RKD & Me, a Campaign to Raise Awareness of Rare Kidney Disease
15 nov. 2022 08h00 HE
|
Travere Therapeutics, Inc.
Developed in collaboration with the rare kidney disease community, RKD & Me aims to amplify the experiences of people living with rare kidney disease. SAN DIEGO, Nov. 15, 2022 (GLOBE NEWSWIRE)...
Travere Therapeutics to Present at Upcoming Investor Conferences
09 nov. 2022 16h30 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that Company management will participate in the following upcoming conferences: Jefferies 2022...
Travere Therapeutics to Report Second Quarter 2022 Financial Results
28 juil. 2022 16h30 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, July 28, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report second quarter 2022 financial results on Thursday, August 4, 2022 before the...
Travere Therapeutics to Present at the 2022 Jefferies Healthcare Conference
02 juin 2022 16h30 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, June 02, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that Company management will present at the 2022 Jefferies Healthcare Conference on Thursday,...
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
14 déc. 2021 16h30 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on December 10, 2021, the Compensation Committee of its Board of Directors granted...
Travere Therapeutics Announces Achievement of Interim Proteinuria Endpoint in the Ongoing Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis
02 févr. 2021 07h00 HE
|
Travere Therapeutics, Inc.
Sparsentan achieved statistically significant response on interim proteinuria endpoint compared to irbesartan after 36-weeks of treatment To date in the study, sparsentan has been generally...